Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03260868 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
A Phase 4 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03260868 is a Phase 4 study that was terminated before completion, run by Sanofi. The registered enrollment target is 15 participants.
The verdict
NCT03260868, a Phase 4 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c). Secondary Objective: To evaluate the appropriate utilization of virtual approach via novel technologies during the study and to assess the effect of the virtual versus traditional study conduct on multiple outcomes in terms of study methodology and diabetes management.
Interventions
- DRUG Insulin glargine, 300 units per milliliter (U/mL)
- DRUG Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2018-11-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03260868
The ClinicalTrials.gov registry entry for NCT03260868 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine, 300 units per milliliter (U/mL) is the first listed.
NCT03260868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03260868 about?
NCT03260868 is a clinical study titled "Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)". Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c). Secondary Objective: To evaluate the appropriate utilization of virtual approach via novel technologies during the stu...
What is the current status of trial NCT03260868?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2017-09-19. Estimated completion is 2018-11-22.
What interventions are being tested in trial NCT03260868?
The interventions under investigation include: Insulin glargine, 300 units per milliliter (U/mL) (DRUG), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) (DRUG).
Who is sponsoring clinical trial NCT03260868?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.